- Solid forms of a JNK inhibitor
-
The present invention provides solid forms of Compound (I), pharmaceutical compositions thereof, and methods for the treatment or prevention of diseases including, but not limited to a liver disease, cancer, a cardiovascular disease, a metabolic disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension, ischemia/reperfusion injury, central nervous system (CNS) injury/damage or a disease treatable or preventable by the inhibition of JNK. In particular, the invention relates to certain novel crystal forms of the compound 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene.
- -
-
Page/Page column 17
(2010/11/24)
-
- METHODS FOR TREATING OR PREVENTING ACUTE MYELOGENOUS LEUKEMIA
-
This invention is generally directed to methods for treating or preventing acute myelogenous leukemia ("AML") comprising administering to a patient in need thereof an effective amount of an Indazole Compound having the structure: or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer or enantiomer thereof, wherein R1, R2 and A are as defined herein.
- -
-
Page/Page column 35-36
(2008/06/13)
-
